Senseonics (SENS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting held virtually to improve access, encourage global participation, and reduce costs.
Board members, executive officers, outside auditors, and counsel were introduced.
Formal business followed the agenda set in the notice and proxy statement.
Board and executive committee updates
Three Class I directors nominated for election to serve until the 2029 annual meeting.
Shareholder proposals
Six proposals presented: election of directors, advisory vote on executive compensation, frequency of compensation votes, ratification of auditors, amendment to increase authorized shares, and approval of the 2026 Equity Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Senseonics
- Revenue surged 140% YoY as a fully implantable CGM advances toward 2028.SENS
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum - Q3 revenue surged 140% as Eversense 365 momentum and the Freedom pipeline advanced.SENS
Investor presentation - Commercial momentum builds toward Gemini in 2027 and Freedom in 2028.SENS
Stifel 2026 Healthcare Conference 2026 - Record $19.6M Q3 revenue lifts FY26 guidance as pump integrations and Freedom advance.SENS
Q3 2026 - Record Q2 revenue and margin growth drive raised 2026 outlook and strong liquidity.SENS
Q2 2026 - Eversense 365 drives growth as pipeline advances toward fully implantable, invisible CGMs.SENS
Investor update - Q1 2026 revenue rose 87% to $11.7M, with gross margin at 59% and net loss at $32.3M.SENS
Q1 2026 - 2025 revenue up 60% to $35.3M, with 65–76% growth expected in 2026.SENS
Q4 2025 - FDA launch of 365-day CGM spurs demand, but Q3 revenue drops and liquidity risks persist.SENS
Q3 2024